Evaluate the Efficacy and Safety of Co-administration of JW0104+C2402 in Patients With Hypertension and Dyslipidemia

JW Pharmaceutical

Status and phase: Enrolling; Phase 3

Conditions: Hypertension; Dyslipidemia

Treatments: Drug: JW0104+C2402; Drug: C2402; Drug: JW0104+C2403

Study type: Interventional

Funder types: Industry

Identifiers

NCT06643130

JW24301

Details and patient eligibility

About

A Multi-center, Randomized, Double-blind, Parallel, Phase Ⅲ Clinical Trial to Evaluate the Efficacy and Safety of Co-administration of JW0104+C2402 in Patients with Hypertension and Dyslipidemia

Full description

To evaluate the efficacy and safety of co-administration of JW0104+C2402 in comparison with co-administration of JW0104+C2403 or C2402 alone in patients with hypertension and dyslipidemia.

Enrollment: 162 estimated patients

Sex: All

Ages: 19+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with hypertension and dyslipidemia

Exclusion criteria

• The subject not meet the specified msBP and LDL-C level

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

162 participants in 3 patient groups

JW0104+C2402

Experimental group

Description:

JW0104+C2402, 8 weeks, QD (Quaque Die)

Treatment:

Drug: JW0104+C2402

JW0104+C2403

Active Comparator group

Description:

JW0104+C2403, 8 weeks, QD

Treatment:

Drug: JW0104+C2403

C2402

Active Comparator group

Description:

C2402, 8 weeks, QD

Treatment:

Drug: C2402